We wish to inform you that the Board of Directors of the Company at its meeting held on Friday, November 14, 2025, has considered and approved the following matters:
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Transgene Biotek approved unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2025. For H1 FY26, revenue from operations stood at Rs. 10.23 lakhs (vs Rs. 10.77 lakhs in H1 FY25), while the company reported a loss before tax of Rs. 82.21 lakhs compared to a profit of Rs. 12.60 lakhs a year ago, driven largely by higher finance costs (Rs. 50.98 lakhs). On a standalone basis, the company's net worth is sharply negative at Rs. -836.90 lakhs, with total assets of Rs. 3,385.86 lakhs and borrowings of Rs. 1,650 lakhs across current and non-current categories. Cash from operations was negative at Rs. -5.77 lakhs and cash balances dropped to Rs. 5.63 lakhs. The Board also approved the 35th AGM notice for December 30, 2025 (via video conferencing), book closure from December 24–30, 2025, and re-appointment of Dr. K. Koteswara Rao as CMD for one year and three Independent Directors for a second term of five years, subject to shareholder approval.
Standalone net worth is negative and H1 losses have widened with negative operating cash flow, signalling serious financial stress – a key concern for shareholders. Ongoing matters at SAT Mumbai, the Appellate Tribunal New Delhi, and an NCLT appeal by a creditor further add to going-concern risk, while the AGM and director re-appointments are procedural and require shareholder voting.